Review



primary antibodies against alk1  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc primary antibodies against alk1
    mRNA expression of gene <t>Alk1</t> in HA-ECs and cAVM-ECs in patients with different ages. Levels of VEGF-A mRNA expression (0.986 ± 0.134) in the HA-ECs were lower than that in cAVM-ECs (8 years) (4.183 ± 0.238) and cAVM-ECs (14 years) (3.834 ± 0.451) (all ∗ p < 0.05). In addition, the levels of VEGF-A mRNA expression were (2.92 ± 0.58) in cAVM-ECs (17 years), (3.04 ± 0.79) in cAVM-ECs (29 years), (3.08 ± 0.37) in cAVM-ECs (32 years), (2.08 ± 0.28) in cAVM-ECs (42 years), (1.97 ± 0.24) in cAVM-ECs (44 years), and (1.97 ± 0.25) in cAVM-ECs (51 years), all of that were higher than that (0.986 ± 0.134) in HA-ECs (all ∗ p < 0.05).
    Primary Antibodies Against Alk1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against alk1/product/Cell Signaling Technology Inc
    Average 94 stars, based on 15 article reviews
    primary antibodies against alk1 - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs"

    Article Title: Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs

    Journal: Frontiers in Cellular Neuroscience

    doi: 10.3389/fncel.2018.00525

    mRNA expression of gene Alk1 in HA-ECs and cAVM-ECs in patients with different ages. Levels of VEGF-A mRNA expression (0.986 ± 0.134) in the HA-ECs were lower than that in cAVM-ECs (8 years) (4.183 ± 0.238) and cAVM-ECs (14 years) (3.834 ± 0.451) (all ∗ p < 0.05). In addition, the levels of VEGF-A mRNA expression were (2.92 ± 0.58) in cAVM-ECs (17 years), (3.04 ± 0.79) in cAVM-ECs (29 years), (3.08 ± 0.37) in cAVM-ECs (32 years), (2.08 ± 0.28) in cAVM-ECs (42 years), (1.97 ± 0.24) in cAVM-ECs (44 years), and (1.97 ± 0.25) in cAVM-ECs (51 years), all of that were higher than that (0.986 ± 0.134) in HA-ECs (all ∗ p < 0.05).
    Figure Legend Snippet: mRNA expression of gene Alk1 in HA-ECs and cAVM-ECs in patients with different ages. Levels of VEGF-A mRNA expression (0.986 ± 0.134) in the HA-ECs were lower than that in cAVM-ECs (8 years) (4.183 ± 0.238) and cAVM-ECs (14 years) (3.834 ± 0.451) (all ∗ p < 0.05). In addition, the levels of VEGF-A mRNA expression were (2.92 ± 0.58) in cAVM-ECs (17 years), (3.04 ± 0.79) in cAVM-ECs (29 years), (3.08 ± 0.37) in cAVM-ECs (32 years), (2.08 ± 0.28) in cAVM-ECs (42 years), (1.97 ± 0.24) in cAVM-ECs (44 years), and (1.97 ± 0.25) in cAVM-ECs (51 years), all of that were higher than that (0.986 ± 0.134) in HA-ECs (all ∗ p < 0.05).

    Techniques Used: Expressing

    Expression of Alk1 proteins in HA-ECs and cAVM-ECs. (A–D) Immunofluorescent staining to detect the Alk1 protein expressed in HA-ECs and cAVM-ECs. (A–C) In HA-ECs, (A) Alk1 protein was stained by Green fluorescent, (B) nuclei was stained by DAPI in Green fluorescent; (C) merge; (D–F) In cAVM-ECs, (D) Alk1 protein was stained by Green fluorescent, (E) nuclei was stained by DAPI in Green fluorescent; the fluorescence intensity in cAVM-ECs was obviously lower than in HA-ECs; (F) merge. Scale bar = 200 μm; (G) Detect the expression of Alk1 by Western blot, (H) expression of Alk1 proteins in the HA-ECs cultures were significantly higher than that in cAVM-ECs in vitro ( ∗ p < 0.05).
    Figure Legend Snippet: Expression of Alk1 proteins in HA-ECs and cAVM-ECs. (A–D) Immunofluorescent staining to detect the Alk1 protein expressed in HA-ECs and cAVM-ECs. (A–C) In HA-ECs, (A) Alk1 protein was stained by Green fluorescent, (B) nuclei was stained by DAPI in Green fluorescent; (C) merge; (D–F) In cAVM-ECs, (D) Alk1 protein was stained by Green fluorescent, (E) nuclei was stained by DAPI in Green fluorescent; the fluorescence intensity in cAVM-ECs was obviously lower than in HA-ECs; (F) merge. Scale bar = 200 μm; (G) Detect the expression of Alk1 by Western blot, (H) expression of Alk1 proteins in the HA-ECs cultures were significantly higher than that in cAVM-ECs in vitro ( ∗ p < 0.05).

    Techniques Used: Expressing, Staining, Fluorescence, Western Blot, In Vitro



    Similar Products

    94
    Cell Signaling Technology Inc primary antibodies against alk1
    mRNA expression of gene <t>Alk1</t> in HA-ECs and cAVM-ECs in patients with different ages. Levels of VEGF-A mRNA expression (0.986 ± 0.134) in the HA-ECs were lower than that in cAVM-ECs (8 years) (4.183 ± 0.238) and cAVM-ECs (14 years) (3.834 ± 0.451) (all ∗ p < 0.05). In addition, the levels of VEGF-A mRNA expression were (2.92 ± 0.58) in cAVM-ECs (17 years), (3.04 ± 0.79) in cAVM-ECs (29 years), (3.08 ± 0.37) in cAVM-ECs (32 years), (2.08 ± 0.28) in cAVM-ECs (42 years), (1.97 ± 0.24) in cAVM-ECs (44 years), and (1.97 ± 0.25) in cAVM-ECs (51 years), all of that were higher than that (0.986 ± 0.134) in HA-ECs (all ∗ p < 0.05).
    Primary Antibodies Against Alk1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against alk1/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    primary antibodies against alk1 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    90
    Santa Cruz Biotechnology primary abs against alk1 antibody
    mRNA expression of gene <t>Alk1</t> in HA-ECs and cAVM-ECs in patients with different ages. Levels of VEGF-A mRNA expression (0.986 ± 0.134) in the HA-ECs were lower than that in cAVM-ECs (8 years) (4.183 ± 0.238) and cAVM-ECs (14 years) (3.834 ± 0.451) (all ∗ p < 0.05). In addition, the levels of VEGF-A mRNA expression were (2.92 ± 0.58) in cAVM-ECs (17 years), (3.04 ± 0.79) in cAVM-ECs (29 years), (3.08 ± 0.37) in cAVM-ECs (32 years), (2.08 ± 0.28) in cAVM-ECs (42 years), (1.97 ± 0.24) in cAVM-ECs (44 years), and (1.97 ± 0.25) in cAVM-ECs (51 years), all of that were higher than that (0.986 ± 0.134) in HA-ECs (all ∗ p < 0.05).
    Primary Abs Against Alk1 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary abs against alk1 antibody/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    primary abs against alk1 antibody - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    mRNA expression of gene Alk1 in HA-ECs and cAVM-ECs in patients with different ages. Levels of VEGF-A mRNA expression (0.986 ± 0.134) in the HA-ECs were lower than that in cAVM-ECs (8 years) (4.183 ± 0.238) and cAVM-ECs (14 years) (3.834 ± 0.451) (all ∗ p < 0.05). In addition, the levels of VEGF-A mRNA expression were (2.92 ± 0.58) in cAVM-ECs (17 years), (3.04 ± 0.79) in cAVM-ECs (29 years), (3.08 ± 0.37) in cAVM-ECs (32 years), (2.08 ± 0.28) in cAVM-ECs (42 years), (1.97 ± 0.24) in cAVM-ECs (44 years), and (1.97 ± 0.25) in cAVM-ECs (51 years), all of that were higher than that (0.986 ± 0.134) in HA-ECs (all ∗ p < 0.05).

    Journal: Frontiers in Cellular Neuroscience

    Article Title: Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs

    doi: 10.3389/fncel.2018.00525

    Figure Lengend Snippet: mRNA expression of gene Alk1 in HA-ECs and cAVM-ECs in patients with different ages. Levels of VEGF-A mRNA expression (0.986 ± 0.134) in the HA-ECs were lower than that in cAVM-ECs (8 years) (4.183 ± 0.238) and cAVM-ECs (14 years) (3.834 ± 0.451) (all ∗ p < 0.05). In addition, the levels of VEGF-A mRNA expression were (2.92 ± 0.58) in cAVM-ECs (17 years), (3.04 ± 0.79) in cAVM-ECs (29 years), (3.08 ± 0.37) in cAVM-ECs (32 years), (2.08 ± 0.28) in cAVM-ECs (42 years), (1.97 ± 0.24) in cAVM-ECs (44 years), and (1.97 ± 0.25) in cAVM-ECs (51 years), all of that were higher than that (0.986 ± 0.134) in HA-ECs (all ∗ p < 0.05).

    Article Snippet: After blocking with 5% non-fat dried milk for 2 h at RT, membranes were incubated with the primary antibodies overnight at 4°C: Primary antibodies against Alk1 (1:1,000, Cell Signaling Technology, Cat No. 31278, United States) and GAPDH (1:5,000, Cell Signaling Technology, Cat No. 51332, United States), each primary antibody was diluted in blocking buffer and then incubated overnight at 4°C.

    Techniques: Expressing

    Expression of Alk1 proteins in HA-ECs and cAVM-ECs. (A–D) Immunofluorescent staining to detect the Alk1 protein expressed in HA-ECs and cAVM-ECs. (A–C) In HA-ECs, (A) Alk1 protein was stained by Green fluorescent, (B) nuclei was stained by DAPI in Green fluorescent; (C) merge; (D–F) In cAVM-ECs, (D) Alk1 protein was stained by Green fluorescent, (E) nuclei was stained by DAPI in Green fluorescent; the fluorescence intensity in cAVM-ECs was obviously lower than in HA-ECs; (F) merge. Scale bar = 200 μm; (G) Detect the expression of Alk1 by Western blot, (H) expression of Alk1 proteins in the HA-ECs cultures were significantly higher than that in cAVM-ECs in vitro ( ∗ p < 0.05).

    Journal: Frontiers in Cellular Neuroscience

    Article Title: Activin Receptor-Like Kinase 1 Combined With VEGF-A Affects Migration and Proliferation of Endothelial Cells From Sporadic Human Cerebral AVMs

    doi: 10.3389/fncel.2018.00525

    Figure Lengend Snippet: Expression of Alk1 proteins in HA-ECs and cAVM-ECs. (A–D) Immunofluorescent staining to detect the Alk1 protein expressed in HA-ECs and cAVM-ECs. (A–C) In HA-ECs, (A) Alk1 protein was stained by Green fluorescent, (B) nuclei was stained by DAPI in Green fluorescent; (C) merge; (D–F) In cAVM-ECs, (D) Alk1 protein was stained by Green fluorescent, (E) nuclei was stained by DAPI in Green fluorescent; the fluorescence intensity in cAVM-ECs was obviously lower than in HA-ECs; (F) merge. Scale bar = 200 μm; (G) Detect the expression of Alk1 by Western blot, (H) expression of Alk1 proteins in the HA-ECs cultures were significantly higher than that in cAVM-ECs in vitro ( ∗ p < 0.05).

    Article Snippet: After blocking with 5% non-fat dried milk for 2 h at RT, membranes were incubated with the primary antibodies overnight at 4°C: Primary antibodies against Alk1 (1:1,000, Cell Signaling Technology, Cat No. 31278, United States) and GAPDH (1:5,000, Cell Signaling Technology, Cat No. 51332, United States), each primary antibody was diluted in blocking buffer and then incubated overnight at 4°C.

    Techniques: Expressing, Staining, Fluorescence, Western Blot, In Vitro